With more than 3 million people in the United States infected with hepatitis C, the price of treating all prevalent cases could potentially top $200 billion. Tapper et al provide support for the idea that appropriate hepatocellular carcinoma cost inputs have been used in recent cost-effectiveness analyses of direct-acting antiviral drugs for chronic hepatitis C infection.
from Cancer via ola Kala on Inoreader http://ift.tt/1IE1lX0
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου